Alpha-Lipoic Acid commonly identified as “ALA” is a powerful natural antioxidant that is often used as a food supplement due to its excellent properties and effects on the nervous system.
Although in the diabetes field, ALA is mainly used for neuropathic treatments, recent studies indicate it as a potentially effective agent in the treatment of type 2 diabetes. It has been demonstrated that ALA can improve insulin sensitivity, helping the body to use glucose more efficiently: this can lead to a reduction in the level of sugar in the blood, improving the management of diabetes.
A study published in 2011, in the journal “Diabetes Care”, examined the effect of Alpha-Lipoic Acid on blood glucose regulation in patients with type 2 diabetes: after 20 weeks of treatment, people undergoing treatment showed a significant reduction in hemoglobin HbA1c levels compared to the control group, as well as a decrease in blood glucose levels.
At the same time, other scientific research has shown that supplementation of Alpha-Lipoic Acid can help reduce the level of oxidative damage in the pancreatic cells, improving their functionality.
The Suractives® division of IPS – International Products and Services – produces and supplies Alpha-Lipoic Acid made with the proprietary and patented MATRIS® technology. Thanks to MATRIS®, the Alpha Lipoic Acid is covered by a membrane capable of conferring greater tolerability at the gastric level, masking the taste and odor, and finally, in the RETARD variants, the controlled release up to 8 hours. This last functionalization is the winning key of the IPS offer which guarantees a high and continuous absorption of the active ingredient which would otherwise be eliminated from the body with a dramatic reduction down to 70% of the bioavailability.
The Alpha-Lipoic Acid produced by IPS allows the RETARD formulation, with a prolonged release, which maximizes the absorption of the nutraceutical active ingredients along the entire gastrointestinal tract.
The MATRIS® technology allows for reaching high concentrations of active ingredients while maximizing the therapeutic efficacy of the supplement. The particle size range and the patented coating technology ensure the uniform diffusion of the active ingredients along the entire gastrointestinal tract, optimizing the absorption of the active ingredients while reducing the sensitization of biological tissues.
IPS supplies bulk ALA MATRIS® that can be used in various formulations and dosage forms such as oro-water dispersible sachets, tablets, stick packs, or single-dose vials with measuring caps.
